Pasithea Therapeutics Corp.
KTTA · XNASCIK 1841330fmd_03M5FEC3P61JV2M3VMQ5T07RRVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2020 to Jun 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | – | – |
| Cost of revenue | 0 | 0 | – | – | – |
| Net interest income | (0) | – | – | – | – |
| Gross profit | (0) | 0 | – | – | – |
| Research and development | – | 3 | 8 | 7 | 8 |
| Selling, general and administrative | 5 | 10 | 8 | 7 | – |
| Operating income | (5) | (13) | (16) | (14) | (21) |
| Interest expense | 0 | 0 | – | – | – |
| Interest and investment income | – | – | 0 | 0 | 0 |
| Other non-operating income (expense) | 2 | 1 | 0 | 0 | 0 |
| Income before taxes | (2) | (12) | (16) | (14) | (20) |
| Net income from continuing operations | – | (12) | (16) | (14) | – |
| Net income | (2) | (14) | (16) | (14) | (20) |